pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KYMRKymera Therapeutics, Inc.

$KYMR121.19+0.05%
Watertown, MA, USupdated 1h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
KT-621
Eosinophilic Asthma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$KYMR121.19+0.05%
16d ago
Kymera Therapeutics, Inc. earnings
Kymera Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase2A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Studyrecruitingn=264
  • phase2A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitisrecruitingn=200
  • phase2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthmarecruitingn=264
  • phase1First-in-human Study of Orally Administered KT-579 in Healthy Adult Participantsrecruitingn=96
  • phase1Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)completedn=22
  • phase1First-in-human Study of Orally Administered KT-621 in Healthy Adult Participantscompletedn=118
  • phase1Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumorscompletedn=56
  • phase1Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumorscompletedn=52
🐶 Hiring Signal
21 open roles at Kymera Therapeutics, Inc. →

Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 21
departmentClinical 4Manufacturing / CMC 2IT & Engineering 1Market Access 1R&D / Discovery 1Biostatistics / Data 1

News

  • Sanofi stops development of Nurix-partnered immune drug
    The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
    biopharma_dive · 15d ago
  • STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
    Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
    stat · 17d ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • North Immunology joins biotech reverse merger boom with Aethlon deal
    Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.
    biopharma_dive · 2mo ago
  • Chutes & Ladders—Legend CEO departs without successor in place
    Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
    fiercebiotech · 3mo ago
identifiers
ticker
$KYMR
SEC CIK
0001815442
country
US
source
sec_tickers
top tags
Asthma1Dermatology1Pulmonology1
mentioned in
5news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?